These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 17369569

  • 1. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.
    J Clin Oncol; 2007 Mar 20; 25(9):1054-60. PubMed ID: 17369569
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
    DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK.
    J Clin Oncol; 2004 Jun 15; 22(12):2452-60. PubMed ID: 15197208
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
    Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, Bongartz R, Berthold F, Schicha H.
    Nuklearmedizin; 2006 Jun 15; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
    [Abstract] [Full Text] [Related]

  • 6. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma.
    Howard JP, Maris JM, Kersun LS, Huberty JP, Cheng SC, Hawkins RA, Matthay KK.
    Pediatr Blood Cancer; 2005 Mar 15; 44(3):232-9. PubMed ID: 15490487
    [Abstract] [Full Text] [Related]

  • 7. 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients.
    Garaventa A, Bellagamba O, Lo Piccolo MS, Milanaccio C, Lanino E, Bertolazzi L, Villavecchia GP, Cabria M, Scopinaro G, Claudiani F, De Bernardi B.
    Br J Cancer; 1999 Dec 15; 81(8):1378-84. PubMed ID: 10604736
    [Abstract] [Full Text] [Related]

  • 8. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
    Mastrangelo S, Tornesello A, Diociaiuti L, Riccardi R, Rufini V, Troncone L.
    Q J Nucl Med; 1995 Dec 15; 39(4 Suppl 1):69-71. PubMed ID: 9002754
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].
    Défachelles AS, Cougnenc O, Carpentier P.
    Bull Cancer; 2011 May 15; 98(5):559-69. PubMed ID: 21609890
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
    Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, Mosse YP.
    Pediatr Blood Cancer; 2011 Dec 15; 57(7):1124-9. PubMed ID: 21495159
    [Abstract] [Full Text] [Related]

  • 13. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
    Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Dela Cruz F, Jahan TM, Linker CA, Damon L, Matthay KK.
    Ann N Y Acad Sci; 2006 Aug 15; 1073():465-90. PubMed ID: 17102115
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.
    J Nucl Med; 2012 Jul 15; 53(7):1155-63. PubMed ID: 22700000
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term results of [131I]metaiodobenzylguanidine treatment of refractory advanced neuroblastoma.
    Hutchinson RJ, Sisson JC, Miser JS, Zasadny KR, Normolle DP, Shulkin BL, Francis IR, Wieland DM, Shapiro B.
    J Nucl Biol Med (1991); 1991 Jul 15; 35(4):237-40. PubMed ID: 1823826
    [Abstract] [Full Text] [Related]

  • 20. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
    Sari O, Uğur O, Emir S, Akyüz C.
    Turk J Pediatr; 2001 Jul 15; 43(1):29-33. PubMed ID: 11297155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.